The IP & Science business of Thomson Reuters announced an agreement with Brazil's Institute for Applied Economic Research (IPEA). This partnership provides IPEA's Direction of Sectorial Studies and Policies for Innovation, Regulation and Infrastructure (DISET) branch with access to the Newport suite of products, supplying them with generic pharmaceutical intelligence as well as with tools for business development and the sourcing of global active pharmaceutical ingredients. DISET will use Newport to find new opportunities to improve Brazil's national pharmaceutical infrastructure -- in research, development and manufacturing -- as well as the quality of its active pharmaceutical ingredients. In addition to the extensive generic drug information available through the Newport suite of products, the group will have access to the Newport Generic Deals module, providing seamless integration of nearly 10,000 generic industry deals since 1999.